Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes. The company's products under development stage include Axo-Lenti-PD, a gene-based treatment for parkinson's disease; OXB-302, which is in pre-clinical stage for the treatment of haematological tumours; OXB-401 that is in pre-clinical stage for the treatment of liver indication; OXB-40X for liver indication; and OXB-40Y for liver indication. The company has partnerships with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium, Immatics, Arcellx, and Vaccines Manufacturing and Innovation Centre. The company also has a research collaboration agreement with Circularis Biotechnologies to identify novel tissue specific promoters for in vivo lentiviral gene therapy products; Virica Biotech for scaling of viral medicines; Isolere Bio provides a platform technology for tackling downstream inefficiencies in the manufacturing of biologics; and BiologIC Technologies provides novel biocomputer system for viral vector development. Oxford Biomedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
